Last updated: January 24, 2026
Summary
This report provides a detailed overview of the proceedings, legal issues, and implications surrounding ACADIA Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. (Case No. 1:20-cv-00986). Filed in the United States District Court, District of Delaware, the case centers on patent infringement related to ACADIA’s pharmacological patent portfolio for Nuplazid (pimavanserin), a drug approved for Parkinson’s disease psychosis.
Case Overview
| Aspect |
Details |
| Jurisdiction |
United States District Court, District of Delaware |
| Filing Date |
March 4, 2020 |
| Parties |
Plaintiff: ACADIA Pharmaceuticals Inc.
Defendant: Teva Pharmaceuticals USA, Inc. |
| Legal Focus |
Patent infringement, declaratory judgment of non-infringement, invalidity defenses |
| Patent Concerned |
U.S. Patent No. 9,915,151 (expiry 2032), related to method-of-use for pimavanserin |
Context and Background
ACADIA holds a portfolio of patents protecting pimavanserin, a selective serotonin inverse agonist used primarily for treating Parkinson’s disease psychosis. Teva challenged ACADIA’s patent rights, asserting that their generic version of pimavanserin does not infringe and that the patent is invalid under prior art.
Drug and Patent Details
| Patent Number |
Issue Date |
Expiry |
Patent Type |
Key Claims |
| 9,915,151 |
March 13, 2018 |
2032 |
Method-of-use |
Use of pimavanserin for treating psychosis |
Significance of the Patent
The '151 patent covers method-of-use claims, crucial for maintaining market exclusivity through patent protections on the prescribed therapy for Parkinson’s psychosis.
Legal Issues & Claims
Core Legal Allegations
- Infringement: Teva’s proposed generic version infringes the '151 patent’s method claims.
- Invalidity: Teva claims the patent is invalid due to obviousness, lack of novelty, and patentable subject matter.
- Declaratory Judgment: Teva seeks a ruling that their generic does not infringe or that the patent is invalid.
ACADIA’s Position
- Asserts the '151 patent's validity and enforceability.
- Contends that Teva's generic infringes on the patent’s claims by utilizing the patented method in its formulations.
Teva’s Defenses
- Argues patent claims lack novelty or are obvious in light of prior art.
- Challenges the patent’s inventiveness or asserts non-infringement through design around strategies.
Timeline and Key Proceedings
| Date |
Event |
Outcome / Status |
| March 4, 2020 |
Complaint filed |
Court initiates proceedings |
| June 2020 |
Patent invalidity defenses raised |
Ongoing discovery process |
| September 2021 |
Preliminary motions |
Pending substantive motions |
| December 2022 |
Summary judgment motions filed |
Awaiting Court ruling |
| Expected 2023 |
Trial / settlement discussions |
Anticipated resolution |
Patent Litigation Strategies and Industry Implications
Patent Enforcement & Challenges
| Strategy |
Description |
Implication |
| Patent Defense |
Affirming validity and infringement |
Preserves market exclusivity |
| Challenge Validity |
Prior art references, obviousness |
Potential for patent invalidation |
| Design-Around |
Developing formulations or methods avoiding patent claims |
Competitive workaround |
Industry Impact
- Market exclusivity for ACADIA remains linked to patent strength.
- Teva’s challenge reflects a broader trend of potential patent disputes in the CNS drug sector.
- Potential settlement or licensing agreements could influence future generic entry.
Patent Disputes in the Pharmaceutical Sector: Trends & Policies
| Trend |
Description |
Policy Implication |
| Increased litigation |
Cost-containment and patent life extension efforts |
Regulatory focus on patent validity |
| Patent challenge pathways |
Inter partes reviews (IPRs) and post-grant proceedings |
Potential for patent invalidation pre-litigation |
| Market exclusivity strategies |
Patent term extensions, data exclusivity |
Encourages innovation but delays generic entry |
Key Legal and Market Considerations
| Consideration |
Relevance |
| Patent duration |
Up to 2032, offering market exclusivity |
| Potential settlement |
Could influence generic market timing |
| Invalidity prospects |
Based on prior art, obviousness, or claim scope |
| Regulatory pathways |
Patent challenges via IPRs or district court |
Comparison with Similar Hatch-Waxman Litigation
| Aspect |
ACADIA v. Teva |
Typical Hatch-Waxman Litigation |
| Type of patent |
Method-of-use |
Composition or formulation |
| Claims at issue |
Method claims |
Compound claims |
| Defenses invoked |
Invalidity: obviousness, novelty |
Invalidity, non-infringement |
| Market implications |
Extended exclusivity |
Streamlined generic entry |
Conclusion and Outlook
The case presents a standard pharmaceutical patent infringement dispute within the evolving landscape of drug patent litigation. The outcome hinges on whether Teva can successfully invalidate or carve around ACADIA’s method claims. Given the high value of Nuplazid and patent protections, resolution may involve settlement, licensing, or final court rulings favoring either party.
Key Takeaways
- Patent strength is crucial for ACADIA’s market exclusivity; the '151 patent encapsulates core claims.
- Teva’s defenses focus on patent invalidity based on prior art and obviousness.
- Strategic patent litigation in pharma often involves parallel IPRs, district court proceedings, and settlement negotiations.
- Market implications are significant; invalidation or infringement findings can alter commercial trajectories and pricing strategies.
- Due diligence for generic entrants must scrutinize patent claims, validity, and design-around opportunities.
FAQs
1. What is the primary patent protecting ACADIA’s Nuplazid?
The '151 patent (U.S. Patent No. 9,915,151) covers the method-of-use for pimavanserin in treating psychosis in Parkinson’s disease, expiring in 2032.
2. How can Teva challenge the patent's validity?
Through patent invalidity defenses, primarily arguing that the patent claims lack novelty, are obvious based on prior art, or fail to meet patentability criteria under 35 U.S.C. §§ 102 and 103.
3. What impact could this litigation have on the availability of generic pimavanserin?
If Teva succeeds in invalidating or designing around the patent, generic versions could enter the market sooner. Conversely, if ACADIA wins, patent exclusivity could be extended until 2032.
4. Are IPR proceedings likely to influence this case?
Yes, IPRs are a common tool in pharma patent disputes; they can lead to patent invalidation without the need for district court litigation and are often coordinated with or precede civil actions.
5. What are the strategic considerations for ACADIA and Teva?
ACADIA aims to defend patent validity and uphold market exclusivity; Teva seeks to challenge patent strength to accelerate generic entry and reduce costs for consumers.
References
[1] U.S. District Court, District of Delaware, Case No. 1:20-cv-00986.
[2] U.S. Patent No. 9,915,151.
[3] FDA NDA 206273, approved March 23, 2016.
[4] Federal Register, “Statutory & Regulatory Patent Exclusivities,” 2019.
[5] Hatch-Waxman Act, 35 U.S.C. §§ 271, 355, 356.
